A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
CONCLUSION: Our findings highlight the substantially low rate of seroprotection in patients with hematological malignancies with a wide range of rates among disease subgroups and different treatments; further highlighting the fact that booster doses might be acquired for these patients to improve immunity against SARS-CoV-2.PMID:35843148 | PMC:PMC9273573 | DOI:10.1016/j.intimp.2022.109046
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Maryam Noori Shadi Azizi Farhan Abbasi Varaki Seyed Aria Nejadghaderi Davood Bashash Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Chronic Leukemia | Chronic Lymphocytic Leukemia | Coronavirus | Covid Vaccine | COVID-19 | Databases & Libraries | Hematology | Leukemia | SARS | Science | Vaccines